Cargando…
BP-1-102 exerts an antitumor effect on the AGS human gastric cancer cell line through modulating the STAT3 and MAPK signaling pathways
BP-1-102, a novel inhibitor of signal transducer and activator of transcription 3 (STAT3), exhibits significant antitumor effects in several malignancies in vitro and in vivo. However, its role in gastric cancer (GC) remains to be elucidated. In the present study, the effect and potential molecular...
Autores principales: | Jiang, Xiaoxia, Tang, Jian, Wu, Mengjie, Chen, Shitu, Xu, Zhenzhen, Wang, Haiyong, Wang, Haohao, Yu, Xiongfei, Li, Zhongqi, Teng, Lisong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423579/ https://www.ncbi.nlm.nih.gov/pubmed/30720080 http://dx.doi.org/10.3892/mmr.2019.9892 |
Ejemplares similares
-
HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer
por: Jiang, Xiaoxia, et al.
Publicado: (2018) -
Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer
por: Lu, Jun, et al.
Publicado: (2015) -
BP‑1‑102 exerts antitumor effects on T‑cell acute lymphoblastic leukemia cells by suppressing the JAK2/STAT3/c‑Myc signaling pathway
por: Ye, Can, et al.
Publicado: (2023) -
GPRC5A: An Emerging Biomarker in Human Cancer
por: Jiang, Xiaoxia, et al.
Publicado: (2018) -
COL12A1, a novel potential prognostic factor and therapeutic target in gastric cancer
por: Jiang, Xiaoxia, et al.
Publicado: (2019)